Legislators call HHS to action on Xtandi march-in rights
More than two dozen lawmakers are putting renewed pressure on the federal government to use its march-in rights to lower the price of prostate cancer drug Xtandi.
The group — led by Sens. Elizabeth Warren (D-MA) and Angus King (I-ME), and Rep. Lloyd Doggett (D-TX) — penned a letter to HHS Secretary Xavier Becerra on Tuesday requesting a “long overdue” public hearing on a petition to lower Xtandi’s price filed by patients more than a year ago. Earlier this month, the petitioners got word that the NIH is still “currently coordinating with HHS to review and assess the information,” according to the letter.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.